Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TFS forms CEE division

This article was originally published in Scrip

Executive Summary

Trial Form Support (TFS), a CRO mainly operating in Europe, has established a division in Budapest, Hungary, which is taking responsibility for the company's business in central and eastern Europe. Dr Zoltan Keleman has been appointed managing director of TFS CEE. The new company, which will initially focus on the management of Phase II and III clinical trials and contract placement services, wants to build commercial collaborations with the industry, academia and healthcare workers. TFS provides clinical trial services for pharmaceutical, biotechnological, medical device, diagnostic and food industries. It has almost 500 employees and offices in the Baltic States, Denmark, Finland, France, Hungary, Italy, the Netherlands, Norway, Portugal, Russia, Spain, Sweden and the UK, as well as in Japan, India and the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC008183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel